AbbVie acquires Celsius Therapeutics to enhance inflammatory disease treatment options
In a significant move within the biotechnology industry, AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, has completed the acquisition of Celsius Therapeutics, Inc., a ... Read More